The extracellular matrix: A new turn-of-the-screw for anti-angiogenic strategies

Trends in Molecular Medicine

Volumn 9, Issue 6, 2003, Pages 256-262

  Sanz, Laura ^a   Álvarez Vallina, Luis ^b  

^a MAYO CLINIC   (United States)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; GELATINASE A; GELATINASE B; GESTONORONE CAPROATE; INTEGRIN; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; MATRIX PROTEIN; TANOMASTAT;

ANGIOGENESIS; CANCER RESEARCH; CELL SURVIVAL; CLINICAL TRIAL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

MURINAE;

EID: 0038265104     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(03)00070-4     Document Type: Article

References (51)

1. Carmeliet, P. (2000) Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389-395
2. Carmeliet, P. and Jain, R.K. (2000) Angiogenesis in cancer and other diseases. Nature 407, 249-257
3. Jain, R.K. et al. (1997) Quantitative angiogenesis assays, progress and problems. Nat. Med. 3, 1203-1208
4. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364
5. Yancopoulos, G.D. et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248
6. Carmeliet, P. et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439
7. Ferrara, N. and Alitalo, K. (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5, 1359-1364
8. Kerbel, R.S. (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21, 505-515
9. Fang, J. et al. (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. U. S. A. 97, 3884-3889
10. Bergers, G. et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744
11. O'Reilly, M.S. et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328
12. O'Reilly, M.S. et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285
13. Pozzi, A. et al. (2000) Elevated matrix metalloprotease and angiostatin levels in integrin α 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. U. S. A. 97, 2202-2207
14. Pozzi, A. et al. (2002) Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21, 272-281
15. Coussens, L.M. et al. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392
16. Overall, C.M. and Lopez-Otin, C. (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657-672
17. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164
18. v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-546
19. Hood, J.D. et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407
20. 5 integrins. Nat. Med. 8, 27-34
21. v integrins. Cell 95, 507-519
22. Cheresh, D.A. and Stupack, D.G. (2002) Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat. Med. 8, 193-194
23. Hynes, R.O. (2002) A re-evaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918-921
24. 1 integrin is essential for teratoma growth and angiogenesis. J. Cell Biol. 139, 265-278
25. 1 integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol. 160, 195-204
26. Boehm, T. et al. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407
27. Rehn, M. et al. (2001) Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 98, 1024-1029
28. Maeshima, Y. et al. (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295, 140-143
29. Eisterer, W. et al. (2002) Unfulfilled promise of endostatin in a gene therapy xenotransplant model of human acute lymphocytic leukemia. Mol. Ther. 5, 352-359
30. Kerbel, R. and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727-739
31. Maniotis, A.J. et al. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752
32. McDonald, D.M. et al. (2000) Vasculogenic mimicry: how convincing, how novel, and how significant? Am. J. Pathol. 156, 383-388
33. Hendrix, M.J. et al. (2002) Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res. 62, 665-668
34. Seftor, R.E. et al. (2001) Cooperative interactions of laminin 5γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metallo-proteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 61, 6322-6327
35. Schwarzbauer, J. (1999) Basement membranes: putting up the barriers. Curr. Biol. 9, R242-R244
36. Stupack, D.G. and Cheresh, D.A. (2002) ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci. STKE 119, PE7
37. St Croix, B. et al. (2000) Genes expressed in human tumor endothelium. Science 289, 1197-1202
38. Castellani, P. et al. (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59, 612-618
39. Nilsson, F. et al. (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 61, 711-716
40. Halin, C. et al. (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20, 264-269
41. Davis, G.E. and Camarillo, C.W. (1995) Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways. Exp. Cell Res. 216, 113-123
42. Kubota, Y. et al. (1988) Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 107, 1589-1598
43. Nomizu, M. et al. (1997) Identification of cell binding sequences in mouse laminin gamma1 chain by systematic peptide screening. J. Biol. Chem. 272, 32198-32205
44. Winter, G. et al. (1994) Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455
45. Yokota, T. et al. (1993) Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res. 53, 3776-3783
46. Sanz, L. et al. (2001) Generation and characterization of recombinant human antibodies specific for native laminin epitopes. Potential application in cancer therapy. Cancer Immunol. Immunother. 50, 557-565
47. Sanz, L. et al. (2002) Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. 9, 1049-1053
48. Álvarez-Vallina, L. (2001) Genetic approaches for antigen selective gene therapy. Curr. Gene Ther. 1, 385-397
49. Sanz, L. et al. Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells. Cancer Immunol. Immunother. (in press)
50. Sanz, L. et al. (2003) A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J. 22, 1508-1517
51. Sanz, L. et al. (2002) Development of a computer-assisted high-throughput screening platform for anti-angiogenic screening. Microvasc. Res. 63, 335-339